メディネット announced business structural reforms effective 30 October 2026, stating that it would discontinue in-house development of regenerative medicine products and concentrate management resources on the cell processing business.
メディネット announced that it would implement business structural reforms effective 30 October 2026 and discontinue in-house development of the regenerative medicine product “MDNT-03.” As a result, the company will review its R&D investment and workforce allocation to strengthen its financial base.
The company explained that it does not intend to withdraw completely from the business, but will concentrate management resources on the cell processing business while keeping future development of regenerative medicine products in view. It indicated its intention to explore the future potential of regenerative medicine products while prioritizing R&D projects with broad applicability.